Patients

VENT-03 Clinical Trials

Phase 2 lupus trial: Now Enrolling

Our Phase 2 clinical study evaluating VENT-03 is enrolling adults with lupus who have active cutaneous manifestations between the ages of 18 and 80 years old.

Learn more here.

If you are interested in joining the trial, click here.

Phase 1 trial in healthy volunteers: Completed

The successfully completed Phase 1 trial in healthy volunteers demonstrated that VENT-03 is safe and well-tolerated. VENT-03’s robust target engagement and favorable pharmacokinetic profile enables once-daily dosing.

Learn more about the Phase 1 trial here.

VENT-02 Clinical Trials

Phase 2 Parkinson’s disease trial: dosing completed

Our Phase 2 clinical trial of VENT-02 enrolled patients with mild to moderate Parkinson’s disease, between the ages of 45 and 90 years old.

Phase 1 trial in healthy volunteers: Completed

In the successfully completed Phase 1 trial, VENT-02 was well-tolerated at clinical doses, with no dose-limiting safety findings or serious adverse events reported. VENT-02 demonstrated full target engagement and potential for once-daily dosing.

Learn more about the Phase 1 trial here.

Expanded Access Statement

Expanded access (compassionate use) is the use of an investigational medicine for patients with serious or life-threatening conditions prior to approval or outside clinical trials. Ventus does not currently have an expanded access program. Please visit clinicaltrials.gov to determine if you qualify for a clinical trial and discuss options and risks with your healthcare provider.